Sacituzumab tirumotecan

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Phase II

Conditions

Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma

Trial Timeline

Jun 1, 2026 → Feb 1, 2030

NCT ID

NCT07438626

About Sacituzumab tirumotecan

Sacituzumab tirumotecan is a phase 2 stage product being developed by Merck for Phase II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07438626. Target conditions include Phase II, Sacituzumab, Tirumotecan.

What happened to similar drugs?

7 of 15 similar drugs in Phase II were approved

Approved (7) Terminated (2) Active (6)

✅Lemborexant + PlaceboEisaiApproved

✅progesterone + ProgesteroneMerckApproved

✅NilotinibNovartisApproved

✅AsciminibNovartisApproved

✅DasatinibBristol Myers SquibbApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07438626	Phase 2	Recruiting	Jun 1, 2026	Feb 1, 2030	Phase II
NCT07458113	Phase 2	Recruiting	May 1, 2026	May 1, 2029	Metastatic Triple Negative Breast Cancers

Competing Products

20 competing products in Phase II

See all competitors

Product	Company	Stage	Hype Score
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Tamsulosin HCl + Solifenacin Succinate + EC905	Astellas Pharma	Phase 1	29
solifenacin succinate + mirabegron + mirabegron/solifenacin succinate	Astellas Pharma	Phase 1	29
Graceptor®	Astellas Pharma	Pre-clinical	26
Lemborexant + Placebo	Eisai	Approved	50
BIW-8962	Kyowa Kirin	Phase 1/2	24
Acalabrutinib	AstraZeneca	Phase 1/2	36
progesterone + Progesterone	Merck	Approved	39
Asciminib	Novartis	Pre-clinical	30
Nilotinib	Novartis	Phase 3	40
Imatinib mesylate	Novartis	Phase 3	32
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate	Novartis	Phase 3	32
ribociclib + Trametinib	Novartis	Phase 1	21
Nilotinib	Novartis	Approved	43
Imatinib	Novartis	Phase 3	40
Nilotinib	Novartis	Approved	43
Gleevec	Novartis	Phase 2	35
Nilotinib + Ruxolitinib	Novartis	Phase 1/2	32
ABL001	Novartis	Phase 3	40
asciminib	Novartis	Phase 2	39